Home › Endometrial Cancer › Illinois › Cicero
Endometrial Cancer clinical trials in Cicero, IL
4 studies for Endometrial Cancer are looking for participants at sites in and around Cicero (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
RecruitingPhase 3
- Rush MD Anderson Cancer Center at Rush Oak Park, Oak Park · 3 mi away
- Northwestern Medicine Oak Brook, Oak Brook · 9 mi away
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- Advocate Christ Medical Center, Oak Lawn · 9 mi away
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Hope and Healing Cancer Services, Hinsdale · 10 mi away
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
RecruitingPhase 2/3
- Dr. Sudarshan K. Sharma, Ltd., Hinsdale · 10 mi away
Endometrial Cancer trials in other cities
- Houston, TX68 studies
- New York City, NY52 studies
- Boston, MA50 studies
- Arlington, VA39 studies
- Nashville, TN38 studies
- Los Angeles, CA34 studies
- St. Louis, MO29 studies
- Philadelphia, PA28 studies
- San Antonio, TX27 studies
- Columbus, OH25 studies
- Oklahoma City, OK25 studies
- Chicago, IL25 studies
Other studies in Cicero
- Non-Small Cell Lung Cancer24 studies
- Lung Cancer17 studies
- Prostate Cancer14 studies
- Cancer (all types)13 studies
- Breast Cancer11 studies
- Acute Myeloid Leukemia11 studies
- Colorectal Cancer10 studies
- Bladder Cancer8 studies
- Melanoma7 studies
- Cardiovascular Disease7 studies
- Metastatic Cancer7 studies
- Multiple Myeloma6 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.